Evaluation of serum FPSA/TPSA and hormone determination combinded with nuclide bone imaging in diagnosis of prostate carcinoma and its recidivation and metastasis

国际放射医学核医学杂志 Pub Date : 2010-11-25 DOI:10.3760/CMA.J.ISSN.1673-4114.2010.06.005

Hu Chenggang, Chen Xiaoyan, Ma Chun-qing, Wang Junhong, Su Li, Deng Yan, Niu Wenqiang

{"title":"Evaluation of serum FPSA/TPSA and hormone determination combinded with nuclide bone imaging in diagnosis of prostate carcinoma and its recidivation and metastasis","authors":"Hu Chenggang, Chen Xiaoyan, Ma Chun-qing, Wang Junhong, Su Li, Deng Yan, Niu Wenqiang","doi":"10.3760/CMA.J.ISSN.1673-4114.2010.06.005","DOIUrl":null,"url":null,"abstract":"Objective To evaluate the clinical value of free prostate antigen (FPSA) , total prostate specific antigen (TPSA) , FPSA / TPSA and serum hormones (PRL, FSH, LH, Prog, T, E2) combined with ECT bone imaging in patients with prostate carcinoma. Methods 44 healthy males, 75 patients of benign prostate disease (including 41 of benign prostatic hyperplasia (BPH) and 25 of HBP with acute urinary retention (BPH + AUR) surgery, 9 of acute prostatitis) , and 48 patients with prostate carcinoma were enrolled in this study. Their Gonadal hormones and TPSA, FPSA, FPSA / TPSA were measured. Results ①The level of TPSA and FPSA in patients with prostate carcinoma or benign prostate disease were significantly higher than in healthy control (t1=11.42, t2=12.01, P 0.05); ④he FSH and LH of gonadal hormones in patients with prostate carcinoma were obviously higher than in patients with benign prostate diseases and healthy control.鈶?Except patients having operation total correction, the gonadal hormones and FSH/LH, T in patients with prostate carcinoma having different treatment programs all had variances before and after therapy; ⑤TPSA and FPSA in patients with prostate carcinoma having bone metastasis were much higher than those without bone metastasis (t/TPSA=5.38, t/fpsA=4.26, P 0.05). Conclusion here was great clinlical value of the determination of TPSA and FPSA in diagnosis of prostate carcinoma, identification of prostate carcinoma and benign prostate disease and in judgment of bone metastasis. The ratio of FPSA /TPSA <0.16 is a proper prediction index for diagnosis of prostate carcinoma, FPSA /TPSA might be <0.16 in healthy ones and patients with acute prostatitis or BPH ; but when FPSA / TPSA <0.16, the risk of prostate cancer would increase; Gonadal hormones is useful biomarkers in diagnosis and treatment in patients with prostate carcinoma. \n \nKey words: \nProstatic neoplasms; Prostate specific antigen Gonadal hormones; Techmetium Tc 99m Medronate","PeriodicalId":59545,"journal":{"name":"国际放射医学核医学杂志","volume":"34 1","pages":"337-343"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际放射医学核医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-4114.2010.06.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To evaluate the clinical value of free prostate antigen (FPSA) , total prostate specific antigen (TPSA) , FPSA / TPSA and serum hormones (PRL, FSH, LH, Prog, T, E2) combined with ECT bone imaging in patients with prostate carcinoma. Methods 44 healthy males, 75 patients of benign prostate disease (including 41 of benign prostatic hyperplasia (BPH) and 25 of HBP with acute urinary retention (BPH + AUR) surgery, 9 of acute prostatitis) , and 48 patients with prostate carcinoma were enrolled in this study. Their Gonadal hormones and TPSA, FPSA, FPSA / TPSA were measured. Results ①The level of TPSA and FPSA in patients with prostate carcinoma or benign prostate disease were significantly higher than in healthy control (t1=11.42, t2=12.01, P 0.05); ④he FSH and LH of gonadal hormones in patients with prostate carcinoma were obviously higher than in patients with benign prostate diseases and healthy control.鈶?Except patients having operation total correction, the gonadal hormones and FSH/LH, T in patients with prostate carcinoma having different treatment programs all had variances before and after therapy; ⑤TPSA and FPSA in patients with prostate carcinoma having bone metastasis were much higher than those without bone metastasis (t/TPSA=5.38, t/fpsA=4.26, P 0.05). Conclusion here was great clinlical value of the determination of TPSA and FPSA in diagnosis of prostate carcinoma, identification of prostate carcinoma and benign prostate disease and in judgment of bone metastasis. The ratio of FPSA /TPSA <0.16 is a proper prediction index for diagnosis of prostate carcinoma, FPSA /TPSA might be <0.16 in healthy ones and patients with acute prostatitis or BPH ; but when FPSA / TPSA <0.16, the risk of prostate cancer would increase; Gonadal hormones is useful biomarkers in diagnosis and treatment in patients with prostate carcinoma. Key words: Prostatic neoplasms; Prostate specific antigen Gonadal hormones; Techmetium Tc 99m Medronate

查看原文本刊更多论文

血清FPSA/TPSA及激素检测联合核素骨显像对前列腺癌及其复发转移的诊断价值

目的探讨游离前列腺抗原(FPSA)、前列腺总特异性抗原(TPSA)、FPSA / TPSA及血清激素(PRL、FSH、LH、Prog、T、E2)联合ECT骨显像在前列腺癌患者中的临床价值。方法选取44例健康男性、75例良性前列腺疾病(包括41例良性前列腺增生(BPH)和25例HBP合并急性尿潴留(BPH + AUR)手术患者、9例急性前列腺炎患者、48例前列腺癌患者。测定各组性腺激素及TPSA、FPSA、FPSA / TPSA。结果①前列腺癌及前列腺良性病变患者TPSA、FPSA水平显著高于健康对照组(t1=11.42, t2=12.01, P 0.05);④前列腺癌患者的FSH、LH水平明显高于前列腺良性疾病患者和健康对照组。鈶?除手术全矫正外，不同治疗方案前列腺癌患者的性激素及FSH/LH、T在治疗前后均有差异;⑤有骨转移的前列腺癌患者TPSA和FPSA明显高于无骨转移的前列腺癌患者(t/TPSA=5.38, t/ FPSA =4.26, P 0.05)。结论TPSA和FPSA的测定对前列腺癌的诊断、前列腺癌和前列腺良性疾病的鉴别以及骨转移的判断具有重要的临床价值。FPSA /TPSA比值<0.16是诊断前列腺癌的合适预测指标，健康人、急性前列腺炎或前列腺增生患者的FPSA /TPSA值可<0.16;但当FPSA / TPSA <0.16时，患前列腺癌的风险增加;性腺激素是前列腺癌诊断和治疗中有用的生物标志物。关键词:前列腺肿瘤;前列腺特异性抗原;性腺激素;Techmetium Tc 99m Medronate

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

国际放射医学核医学杂志

自引率

0.00%

发文量

2362